Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children.
about
Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumoniaThe potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experiencePneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.Surveillance of invasive infection in children and adults admitted to QECH, Blantyre, 1996-2002
P2860
Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Defining the potential impact ...... cted and -uninfected children.
@en
Defining the potential impact ...... cted and -uninfected children.
@nl
type
label
Defining the potential impact ...... cted and -uninfected children.
@en
Defining the potential impact ...... cted and -uninfected children.
@nl
prefLabel
Defining the potential impact ...... cted and -uninfected children.
@en
Defining the potential impact ...... cted and -uninfected children.
@nl
P1476
Defining the potential impact ...... cted and -uninfected children.
@en
P2093
Elise Cumin
P304
P356
10.1097/00006454-200205000-00009
P577
2002-05-01T00:00:00Z